Offringa R - Search Results

1

C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L.

Fournel S, Wieckowski S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. Fournel S, et al. Among authors: offringa r. Nat Chem Biol. 2005 Dec;1(7):377-82. doi: 10.1038/nchembio746. Nat Chem Biol. 2005. PMID: 16370373

2

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. Schoenberger SP, et al. Among authors: offringa r. Nature. 1998 Jun 4;393(6684):480-3. doi: 10.1038/31002. Nature. 1998. PMID: 9624005

3

The role of CD40 in peripheral T cell tolerance and immunity.

Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: offringa r. J Mol Med (Berl). 2000;78(7):363-71. doi: 10.1007/s001090000126. J Mol Med (Berl). 2000. PMID: 11043379 Review.

4

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. Diehl L, et al. Among authors: offringa r. Nat Med. 1999 Jul;5(7):774-9. doi: 10.1038/10495. Nat Med. 1999. PMID: 10395322

5

CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.

Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. Toes RE, et al. Among authors: offringa r. Semin Immunol. 1998 Dec;10(6):443-8. doi: 10.1006/smim.1998.0147. Semin Immunol. 1998. PMID: 9826577 Review.

6

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Melief CJ, et al. Among authors: offringa r. Immunol Rev. 2002 Oct;188:177-82. doi: 10.1034/j.1600-065x.2002.18816.x. Immunol Rev. 2002. PMID: 12445291

7

Peptide-based cancer vaccines.

Melief CJ, Offringa R, Toes RE, Kast WM. Melief CJ, et al. Among authors: offringa r. Curr Opin Immunol. 1996 Oct;8(5):651-7. doi: 10.1016/s0952-7915(96)80081-1. Curr Opin Immunol. 1996. PMID: 8902390 Review.

8

Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.

Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE. Boonman ZF, et al. Among authors: offringa r. J Immunol. 2004 Feb 1;172(3):1567-74. doi: 10.4049/jimmunol.172.3.1567. J Immunol. 2004. PMID: 14734736

9

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. van Mierlo GJ, et al. Among authors: offringa r. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. doi: 10.1073/pnas.082107699. Epub 2002 Apr 2. Proc Natl Acad Sci U S A. 2002. PMID: 11929985 Free PMC article.

10

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ. van Mierlo GJ, et al. Among authors: offringa r. J Immunol. 2004 Dec 1;173(11):6753-9. doi: 10.4049/jimmunol.173.11.6753. J Immunol. 2004. PMID: 15557168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page